Adam Jonathan Savitz MD
Assistant Attending Psychiatrist, NewYork-Presbyterian Hospital. Clinical Assistant Professor of Psychiatry (Courtesy), Weill Cornell Medical College, Cornell University.
Join to View Full Profile
21 Bloomingdale RdWhite Plains, NY 10605
Phone+1 914-997-4394
Fax+1 914-682-6906
Dr. Savitz is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Mass General Brigham/Massachusetts General Hospital/McLean HospitalResidency, Psychiatry, 1995 - 1998
David Geffen School of Medicine at UCLAClass of 1994
Certifications & Licensure
NY State Medical License 2001 - 2026
Clinical Trials
- Effects of Risperdal Consta on Ability to Benefit From Social Skills Training in Schizophrenia Start of enrollment: 2005 Sep 01
Publications & Presentations
PubMed
- 12 citationsTreatment effect and safety of seltorexant as monotherapy for patients with major depressive disorder: a randomized, placebo-controlled clinical trial.Sofie Mesens, Iva Kezic, Peter Van Der Ark, Mila Etropolski, Gahan Pandina
Molecular Psychiatry. 2025-06-01 - Response to Commentaries.William P Horan, Amir Kalali, Stephen K Brannan, Wayne Drevets, Atul Mahableshwarkar
Schizophrenia Bulletin. 2025-03-14 - 9 citationsTowards Enhancing Drug Development Methodology to Treat Cognitive Impairment Associated With Schizophrenia and Other Neuropsychiatric Conditions: Insights From 2 Decad...William P Horan, Amir Kalali, Stephen K Brannan, Wayne Drevets, Matthew Leoni
Schizophrenia Bulletin. 2025-03-14
Journal Articles
- The Open Translational Science in Schizophrenia (OPTICS) Project: An Open-Science Project Bringing Together Janssen Clinical Trial and NIMH DataEva C Guinan, Joseph S Ross, Adam J Savitz, Nature
Press Mentions
Alto Neuroscience Identifies Biomarker and Reports Positive Pharmacodynamic Results from Exploratory Phase 2 Proof-of-Concept Trial of ALTO-203June 26th, 2025- Alto Neuroscience Presents New Data Leveraging EEG and Machine Learning to Predict Individual Response to Antidepressants at the 61st Annual Meeting of the American College of NeuropsychopharmacologyDecember 8th, 2022
- Alto Neuroscience Announces Enrollment Completion in Phase 2b Study of ALTO-100 in Major Depressive DisorderJuly 17th, 2024
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
